Keep pulling the thread on Trip.
The U.S. is 90% reliant on India for its supply of pharmaceutical precursors and generic drugs.
India is 100% reliant on China for its supply of pharmaceutical precursors.
The U.S. is effectively 100% reliant on China for pharmaceutical precursors due to India's dependence on Chinese supply.
The United States possesses 95% of the rare earth raw materials it needs within the contiguous 48 states.
The United States lacks the domestic mid-supply chain processing capacity for rare earth materials.
Trip predicts that China will never completely cut off the supply of rare earths to the United States.
The United States can become 100% self-reliant in the manufacturing and processing of critical minerals.
The United States produces practically no generic drugs domestically.
The current U.S. administration's industrial policy involves taking equity positions in companies it significantly invests in, rather than only providing grants.
Trip believes the government's investment in Intel should have been rejected in favor of a competitor like Texas Instruments acquiring or absorbing the assets.
Recent high-level diplomatic talks between the U.S. and China did not address rare earth supply chains in depth, focusing instead on agricultural products like soybeans and meat.
Reshoring all manufacturing to the United States is not realistic because the domestic supply chains for many industries, such as textiles, do not exist.